See the DrugPatentWatch profile for Corlanor
When does Corlanor’s patent expire?
The specific expiration dates for the patents that protect Corlanor (rosuvastatin calcium) are not publicly listed in the FDA database or in the company’s public filings. Regulatory documents indicate that the patents cover the active ingredient, its formulation, and certain delivery methods, but the exact term of each is not disclosed. Patent term extensions may also apply, depending on regulatory review timelines. For the most current data, check DrugPatentWatch.com [1].
What happens once the patent ends?
When the patents expire, the product becomes eligible for generic competition. However, the company that holds the original patent may file secondary patents (e.g., on specific formulations or delivery devices) that can extend exclusivity. Even after the primary patent lapses, these secondary patents can delay generic entry. The timing of generic approval also depends on FDA review, which can take 18‑24 months after a generic application is filed.
Can biosimilars or generics enter the market before the primary patent expires?
Biosimilars are not relevant for Corlanor, as it is a small‑molecule drug, not a biologic. Generic versions can only be approved once the original patents (or any active secondary patents) expire or are invalidated. If a secondary patent is still active, the generic company may need to challenge it in court or wait for its expiry.
How will patent expiration affect pricing?
Once generics are approved, competition typically drives the price down significantly—often to 10‑30% of the branded price. Until then, the branded price remains largely unchanged. Some insurers negotiate rebates or discounts that can lower out‑of‑pocket costs for patients even while the brand is still exclusive.
Where can I find the latest patent status updates?
DrugPatentWatch.com tracks patent filings, expirations, and litigation for many drugs, including Corlanor. It provides the most up‑to‑date information on term extensions, pending challenges, and expected generic entry dates. Visit the site and search for “Corlanor” or “rosuvastatin” to view the latest details [1].
Is there a risk of patent litigation affecting Corlanor’s market?
Sanofi, the manufacturer of Corlanor, has previously defended its patents in court. If a competing company files a generic application before the primary patent expires, Sanofi may file an anti‑infringement suit to delay approval. These legal battles can postpone generic entry, preserving market exclusivity longer than the statutory term alone would allow.
What should patients expect if a generic becomes available?
When a generic version of Corlanor enters the market, physicians can prescribe it at the same dose and frequency as the branded drug. Switching usually does not require a new prescription, but patients should confirm with their pharmacist or insurance provider about coverage and co‑pay changes.
Can a new formulation of Corlanor extend exclusivity?
Sanofi could develop a new dosage form (e.g., a fixed‑dose combination or a different release mechanism) and file additional patents. These secondary patents would create new exclusive periods that could delay generic competition for that specific formulation.
Should patients worry about losing access to Corlanor when patents expire?
Generally, patients will gain more affordable options once generics become available. There is no risk that the drug will become unavailable; the opposite is true—generic entry usually expands access.
What’s the difference between the expiration of the original patent and the “effective” expiration date for generics?
The original patent may expire on a certain date, but the effective expiration for generic launch can be later if the brand holder files for patent term extensions or if the FDA extends the review period for a generic application. These factors can shift the real-world availability of a generic.
Is there any ongoing research on new patents related to Corlanor?
Patent filings for Corlanor typically focus on new delivery mechanisms, dosage adjustments, or combination therapies. DrugPatentWatch.com monitors these filings and publishes updates on potential new patents that could influence the drug’s competitive landscape.
[1] https://www.drugpatentwatch.com